Lineage Q4 net income $0.9M, full-year loss $63.5M; cash runway into Q2 2028

Lineage Cell Therapeutics, Inc.

Q4 2025 revenue $6.6M (up from $2.9M YoY); net income $0.9M ($0.004 EPS) vs net loss $3.3M ($0.02 loss) in Q4 2024.
Full-year 2025 net loss $63.5M ($0.28/share) vs $18.6M ($0.09/share) in 2024; driven by non-cash warrant remeasurement ($37.9M) and VAC impairment ($14.8M).
Cash $55.8M at Dec 31, 2025; plus $5.4M from warrant exercises in March 2026; expected to support operations into Q2 2028.
Achieved first milestone under Roche/Genentech collaboration for OpRegen; 36-month Phase 1/2a data shows sustained visual acuity gains.
Launched Type 1 diabetes research initiative; treated first chronic SCI patient in OPC1 DOSED study with no safety events at 180 days.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lineage Cell Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2025.

Period: quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 5, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025

View on SEC.gov

Browse all earnings releases →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-093948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.